DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education. Busy physicians, nurses, pharmacists and other professionals want...
Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both...
In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned...
